High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hematological side-effect. Amifostine is a cytoprotector which prevents toxicity induced by anticancer therapy. We prospectively compared two groups of patients who either received (group A, n = 21) or did not receive (group B, n = 20) amifostine (740 mg/m 2 ) before HDM (200 mg/m 2 ) followed by autologous peripheral blood progenitor cell transplantation. The occurrence of severe oral mucositis was significantly decreased in group A in comparison to group B (33% vs 65%, P Ͻ 0.05). Six patients in group A required opioid analgesic therapy during a mean period of 4.8 days as compared to eight patients for 6.5 days in group B (P = NS). Delayed vomiting was less frequent in group A (43% vs 70%, P = 0.07) and significantly less severe in group A (grade 2-4) vomiting: two patients vs nine patients, P Ͻ 0.02). No difference was observed between the two groups in either hematological toxicity after HDM or in response rate. Grade I emesis was the only immediate side-effect observed after amifostine administration. We conclude that amifostine can reduce mucositis induced by HDM.
Introduction
Before the 1990s, the standard treatment for multiple myeloma was a combination of alkylating agents and prednisone. The response rate to this treatment ranged between 40 and 60%, but the median duration of survival did not exceed 3 years. 1, 2 Multidrug regimens with conventional doses of alkylating agents with vincristine and doxorubicin had not demonstrated better results than therapy with melphalan and prednisone. 3 In the late 1980s, high-dose melphalan (HDM) (140 to 200 mg/m 2 ) was reported to induce a higher rate of response, 4, 5 and to improve response rate, event-free survival and overall survival. 6 The major toxicities of HDM are myeloid aplasia and mucositis. The combined use of peripheral blood stem cells instead of bone marrow progenitors and hematopoietic growth factors has considerably shortened the period of profound aplasia. However, high-grade mucositis, the major non-hematological toxicity of HDM remains a limitation to this therapeutic approach. At the dose of 220 mg/m 2 occurrence of oral mucositis ranged between 65 and 70% in patients and lasted for a median time of 8 days. 7, 8 Investigational agents such as keratinocyte growth factor and interleukin 11, are actually under development to specifically interfere with the mucosal damage induced. 9 Amifostine (WR-2721) is an organic thiophosphate compound which selectively protects normal tissue from the cytotoxic damage induced by anticancer agents. 10 The protective effect of amifostine was first demonstrated in cells exposed to radiation. 11 Interest in the potential value of amifostine in cancer therapeutics further increased when it was recognized in phase II and phase III clinical trials that amifostine also protected normal tissues, but not tumor cells against the toxic effects of several chemotherapeutic agents, [12] [13] [14] [15] [16] [17] [18] [19] reducing the occurrence and severity of neutropenia and other non-hematological toxicities without affecting anti-cancer efficacy. The principal short-term sideeffects described during amifostine administration are emesis, nausea, hypotension, hypocalcaemia and flu-like symptoms. 4, [20] [21] [22] In this prospective, comparative non-randomized controlled phase II study, the main criterion assessed was the efficacy of amifostine against the occurrence and severity of mucositis. Secondary criteria evaluated in this study were (1) use of opioids prescribed for mucositis; (2) delayed gastro-intestinal toxicity (emesis and diarrhoea);
Patients and methods
Between September 1999 and December 2001, 41 patients with stage III multiple myeloma were treated in the Haematology Department of the Centre Hospitalier Lyon-Sud with high-dose melphalan (HDM) at 200 mg/m 2 followed by an autologous peripheral blood progenitor cell (PBPC) transplant. All these patients were asked to participate in a trial consisting of the administration of amifostine (740 mg/m 2 ) immediately prior to melphalan administration in order to reduce the occurrence of mucositis. Twenty-one patients agreed to participate in this trial (group A) and 20 patients refused. These latter patients were analyzed as the control group of the study (group B).
Patient characteristics at diagnosis (Table 1)
The sex ratio showed a slight male preponderance (1.4), with a median age of 56 years (range 27-68). More than 80% of the patients had a good performance status (ECOG Table 1 Characteristics of patients who received (group A) or did not receive (group B) amifostine at diagnosis. P value compared the presence and the absence of the characteristics Conditioning regimens used for PBPC collection are described in Table 1 .
Amifostine administration
All patients in group A gave informed consent prior to amifostine administration. The scheduled dose of amifostine was administered as a 10-min intravenous (i.v.) infusion using a central venous catheter, 30 min before starting the 200 mg/m 2 HDM infusion. Adequate hydration was given for 24 h before the treatment. As previously recommended, 22 ,23 the patient was lying in bed during the infusion and the baseline blood pressure was controlled and rechecked every 3-5 min. PBPC reinfusion was performed 48 h after the melphalan infusion.
Antiemetic prophylaxis with methylprednisolone (40 mg i.v.), dipotassic clorazepate (20 mg i.v.) and granisetron (3 mg i.v.) was given before amifostine infusion in group A and before the HDM infusion in group B. Amifostinerelated side-effects such as nausea/vomiting and hypotension were evaluated according to the WHO/ECOG scale. 24 
Evaluation of transplant-related toxicity
Oral mucositis was the main criterion assessed in our study. Mucositis was defined with a daily examination of the mouth and throat using the WHO scale. 24 Mucositis was scored as grade 0 when absent, grade 1 in the presence of painless erythema, grade 2 in cases of painful erythema and/or ulcers with the ability to eat, and as grade 3 and 4 when painful mucositis required i.v. hydration and parenteral nutrition, respectively. Mucositis requiring analgesic opioid therapy was specifically recorded.
Other criteria such as diarrhea, nausea, emesis and anorexia were also evaluated. Nausea was precisely evaluated as nausea requiring occasional treatment or permanent i.v. treatment. Emesis was defined according to the WHO scale. 24 Severity of diarrhea was classified according to the WHO scale, 24 and duration was also recorded. Anorexia was evaluated as grade 0 when absent, as grade 1 and 2 in cases of loss of appetite or decreased oral intake, as grade 3 when requiring i.v. fluids, and as grade 4 when requiring parenteral nutrition. 24 Hematological toxicity was assessed by the duration of polymorphonuclear (neutrophil) count under 1000 ϫ 10 9 /l, by the hematopoietic reconstitution in terms of days after the transplant to achieve a polymorphonuclear cell of 1000 ϫ 10 9 /l and a platelet count of 20 000 and 50 000 ϫ 10 9 /l. Transfusion with red cells and platelets was evaluated.
Presence of fever, infections, type of infections, and number of patients receiving antibiotics were recorded, as well as total duration of hospitalization.
Response criteria and statistical analysis
Pre-and post-transplant disease status was assessed according to the ECOG criteria for myeloma patients. Residual disease was assessed by amount of monoclonal component on serum and/or urine electrophoresis, bone marrow biopsy and vertebral and/or bone magnetic resonance imaging (MRI) before transplant and at 6-8 weeks after transplant. Complete remission (CR) was defined as the disappearance of all clinical, biological and histological evidence of myeloma. Partial response (PR) was defined as a decrease in symptoms (bone pain) associated with a decrease of more than 50% of the monoclonal component, normalization of hypercalcemia, and less than 5% marrow involvement by myeloma. Non-response (NR) was defined as a decrease in symptoms (bone pain) associated with a decrease of less than 50% of the monoclonal component, normalization of
Bone Marrow Transplantation hypercalcemia, and non-appearance of new bone lesions. Progression was defined as appearance of new bone lesions or appearance or aggravation of anemia, renal failure or hypercalcemia, or an increase in level of the monoclonal component.
Amifostine efficacy was evaluated by performing the Mann-Whitney U-test for continuous variables and the Fischer's exact test for discrete variables. Occurrence and severity of transplant-related toxicity, use of opioid analgesic, parenteral nutrition and antibiotics, duration of hospitalization were analyzed and compared between the two groups. P values Ͻ0.05 were considered as indicating statistically significant differences. All statistical analyses were performed using Statistica software (version 6, 2001 edition).
Results

Amifostine-induced side-effects
Transient emesis (grade 1) was observed in nine (43%) patients. We observed no symptoms relating to hypocalcemia, such as paresthesia or neuromuscular irritability, or hypotension. All amifostine infusions were performed as planned.
Non-hematological toxicity (Table 2)
The occurrence of painful oral mucositis (grade 2 to 4) was significantly lower in group A than in group B (33% vs 65%, P = 0.047) (Figure 1 ). Analgesic therapy with opioids was used in a non-statistically different number of patients between the two groups (six patients (28%) in group A vs eight patients (40%) in group B, P = 0.32), and the median duration of opioid treatment was slightly reduced when amifostine was administered (4.8 days in group A vs 6.5 days in group B, P = NS) (Figure 2) .
Occurrence of diarrhea was not different, occurring in 43% of patients in group A vs 50% of patients in group B (P = NS). The median duration of diarrhea was 3 and 4 days in groups A and B, respectively. Among these patients, two patients in group A and two in group B had Clostridium difficile infection.
Six patients treated with amifostine had no episodes of nausea or emesis, compared to two patients treated without amifostine. The occurrence of delayed nausea (28% in group A vs 20% in group B) or emesis (43% in group A vs 70% in group B) was not statistically different between the two groups (P = 0.07), but the number of patients with severe emesis (grade 2-4) was significantly lower in group A than in group B (9% vs 45%, P Ͻ 0.02).
Severe anorexia requiring parenteral nutrition was the most frequent side-effect of HDM and was identical in the two groups (76% vs 80%).
Hematological toxicity and engraftment kinetics
The median number of PBPCs infused did not differ between the two groups (Table 1) , with a median number of 5.8 ϫ 10 6 /kg and 6 ϫ 10 6 /kg CD34 + cells infused per patients in group A and in group B, respectively (P = NS). 
Grade II 33%
Grade 0 67%
Group B Grade IIIIV 10%
Grade II 55%
Grade 0 35%
P value = 0.047 Figure 1 Occurrence of painful oral mucositis in patients who received (group A) or did not receive (group B) amifostine.
Amifostine did not affect hematological recovery (Table  3 ). All patients in this study had successful engraftment. An absolute neutrophil count (ANC) Ͼ1 ϫ 10 9 /l was reached after a median time of 12.5 and 12 days after transplant in group A and group B, respectively. The median duration of neutropenia (ANC Ͻ0.1 ϫ 10 9 /l) was 7 days in the 41 patients. Platelet recovery, measured as the median time to achieve a platelet level Ͼ20 ϫ 10 9 /l and platelet level Ͼ50 ϫ 10 9 /l did not differ between the two groups (12 and 13 days, respectively). Red blood cell and platelet transfusion requirements did not differ between the two groups either (P = 0.32 and 0.13, respectively).
Fever Ͼ38.5°C was observed in 38 (93%) patients without any statistical differences between the two groups. The occurrence of documented infections was similar in the two groups (four patients in group A vs four patients in group B). Gram-positive bacteria were isolated in the three patients with septicemia.
Supportive care did not differ between the two groups. Antibiotic prophylaxis and treatment were similar in the two groups. The median duration of hospitalization did not differ: 17 days in group A (range, 13-19 days) and 16.5 days in group B (range, 13-28 days) (P = NS).
Clinical course and outcome
Pre-transplant disease status was similar in terms of prior response obtained with conventional chemotherapy (CR + 773 PR: 18 patients in group A vs 17 patients in group B) (Table  1) . However, the number of CRs achieved in group A was significantly higher than in group B (five patients vs 0 patients, P = 0.02). Evaluation of response after HDM and auto-transplant showed no statistical difference between the two groups, with 95% responses in group A (CR, 10 patients; PR, nine patients) and 94% responses in group B (CR, four patients; PR, 13 patients) (P = 0.47) ( Table 4 ). The median time of follow-up for all patients was 18 months (range, 7.5 months-5.5 years). Twelve patients progressed during this time (eight patients in group A and four patients in group B). Two patients died of disease, one in each group.
Discussion
This prospective study compared two groups of patients with multiple myeloma treated with HDM and PBPC autotransplantation with or without protective amifostine treatment. Tolerance to amifostine was acceptable. We did not observe any severe side-effects, such as hypotension. The main effect was grade 1 emesis, in spite of systematic antiemetic prophylaxis, including a multidrug i.v. combination with a setron (anti-5 HT3 receptors) compound, steroids and anxiolytics.
Comparison of the two groups, with regard to non-hematological toxicity, suggests that amifostine exerts a protective role on epithelial and mucosal tissue at the scheduled dose of 740 mg/m 2 . This is confirmed in the present study by the significant decrease in the occurrence of severe (grade 2-4) oral mucositis. Several other studies have shown that amifostine, at this dosage or higher (910 mg/m 2 ), significantly improves the mucosal side-effects of high-dose chemotherapy in hematological malignancies, 25 as well as in solid tumors. 26, 27 Below this dosage, the effect does not seem to be beneficial, as recently presented by Campilho et al 28 in a study in which amifostine was administrated at 300 mg/m 2 . In this study no difference in the occurrence of mucositis was observed between treated and untreated patients. 28 Besides the dose, the second point described as essential for obtaining a cytoprotective effect on normal tissues is the amifostine administration schedule. Human pharmacokinetic studies have demonstrated that 90% of the drug has disappeared from the plasma compartment 6 min after a 15-min amifostine intravenous administration. 29 Moreover, animal studies have shown that maximal tissue concentrations of WR-1065, the active metabolite, occur 5 to 15 min following administration with a half-life measured at less than 10 min. 22 These data suggest that amifostine must be given shortly before administration of the anticancer drug or radiation from which protection is required. 22, 29 Gastrointestinal side-effects such as delayed nausea and emesis were observed with a slight difference in favor of the group treated with amifostine, particularly regarding the severe emesis. The patients treated with amifostine seemed to have less episodes and significantly less severe vomiting than the other group. Other investigators have also reported a significant decrease in the occurrence of delayed nausea, vomiting and diarrhea. 25, 27 Amifostine has previously been demonstrated to reduce chemotherapy-induced hematological toxicity. 12, 16 In the current study with prophylactic administration of G-CSF, duration of neutropenia, granulocyte engraftment, and toxicity to platelets were similar in both treatment arms. Moreover, we observed no differences between the two groups in terms of occurrence of infections. This experience seems to be in contrast to that of Shpall et al 30 in which ex vivo treatment of marrow with amifostine significantly shortened the time of recovery. Our study was restricted to a small number of patients, which is probably the reason why we were unable to detect differences between the two groups in term of hemotological toxicity. In a larger group reported by Capelli et al, 25 a decrease of the number of infections and severe sepsis was observed in the group receiving amifostine. This suggests a role played by mucositis in increasing the risk of sepsis in neutropenic patients, as reported by Pico et al. 31 Protection of mucosal barrier integrity by amifostine should logically result in a lower incidence of severe sepsis. This could also result in a reduction in the duration of hospital stay, which Hartmann et al 27 reported as being significant in a randomized study of 40 patients with solid tumors treated with chemotherapy with or without amifostine.
Amifostine is reported to selectively protect normal but not tumor tissue against cytotoxic damage induced by some anticancer agents and radiation therapy. 32, 33 In the present series we confirmed that amifostine did not affect anti-cancer treatment efficacy, obtaining an identical response rate to treatment in the arm given amifostine and in the untreated arm. Nevertheless, these negative results must be confirmed by a more powerful, larger study.
In summary, the results of this phase II study to evaluate the effect of amifostine on a homogeneous population of patients with stage III myeloma treated with HDM and autologous transplantation, suggest that amifostine can reduce the severity of the acute side-effects of high-dose chemotherapy by decreasing the occurrence of severe mucositis. Furthermore, administration of amifostine did not add toxicity, particularly with regard to delayed emesis, and did not affect the response to anticancer treatment. These results clearly warrant larger randomized trials to verify the efficacy of amifostine in this setting. The ability of amifostine to reduce supportive care costs also requires confirmation by a cost analysis.
